Budecort

Basic Budecort information

• INN (international nonproprietary name): budesonide.
• Brand names available in the United Kingdom: Pulmicort, Entocort, Budenofalk, Rhinocort; generic budesonide inhalers.
• ATC code: R03BA02 for inhaled respiratory use; A07EA06 for gastrointestinal/enteric forms.
• Forms and strengths: inhaler 100 μg/200 μg/400 μg per dose; nebules/respules 0.25 mg, 0.5 mg, 1 mg per 2 ml; capsules 3 mg (Entocort) and 9 mg enteric courses; rectal foam 2 mg.
• Manufacturers in the United Kingdom: AstraZeneca (Pulmicort), Tillotts/Falk (Budenofalk), Cipla and other generic manufacturers.
• Registration status in the United Kingdom: Multiple budesonide products are registered with the MHRA; prescription-only medicines across forms.
• OTC / Rx classification: Prescription only (Rx) for inhaled, oral and rectal products in the UK.

Legal status and availability in the UK

In our online pharmacy, Budecort is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.

Clinical effectiveness in the UK

Patients ask whether budesonide actually improves day‑to‑day control on the NHS.

• Regular use of inhaled budesonide 200–800 µg/day improves day‑to‑day asthma control.
• Correct inhaler technique is essential for symptom control.
• Entocort and Budenofalk enteric/rectal forms used in secondary care can induce remission in 8–12 weeks with fewer systemic steroid adverse effects than older systemic regimens.

MHRA guidance supports regular review and stepping down treatment once stable control is sustained.

Indications and expanded uses

Patients want clarity on what budesonide is licensed for, and when clinicians use it off‑label.

Licensed uses in the UK include inhaled budesonide for asthma maintenance across adult and paediatric doses, nasal sprays for allergic rhinitis, and enteric capsules (Entocort 3 mg capsules for maintenance courses and 9 mg regimen for induction in ileocaecal Crohn’s).

Rectal formulations such as Budenofalk foam and enemas are used for distal ulcerative colitis and proctitis.

Nebulised respules and nebules (0.25–1 mg/2 ml) are used in children or severe hospitalised respiratory presentations under secondary‑care guidance.

Other uses in UK practice include inhaled budesonide in certain viral respiratory illness protocols and specialist topical GI adaptations for microscopic colitis.

• Not appropriate as sole therapy for acute severe asthma attacks.
• In pregnancy, inhaled budesonide is often preferred to systemic corticosteroids when clinically indicated, with obstetric involvement advised.

Composition and brand landscape

Which brands should patients expect to see at the pharmacy counter?

The active ingredient is budesonide (INN; Budesonidum in Latin).

Key brands in the UK include Pulmicort (AstraZeneca) in Turbuhaler and respule forms, Entocort for GI use, Budenofalk for enteric and rectal formulations, and Rhinocort or Budenase for nasal therapy.

Budecort is a budesonide brand made by Cipla; other manufacturers include AstraZeneca and Tillotts/Falk.

Contraindications and special precautions

People understandably worry about safety, especially long‑term effects and use in special groups.

Absolute contraindications are hypersensitivity to budesonide or excipients, and using inhaled budesonide as sole therapy during a severe acute asthma attack.

Relative precautions include active untreated infections such as pulmonary tuberculosis, fungal or viral respiratory infections, significant hepatic impairment and conditions such as osteoporosis, glaucoma and cataracts where monitoring is necessary.

Pregnancy: inhaled budesonide is often preferred where inhaled corticosteroids are required, but an obstetric review is advised for systemic courses.

MHRA advises regular review on long‑term high‑dose therapy because of the potential for HPA‑axis suppression; taper systemic or enteric courses to avoid adrenal crisis.

Dosage guidelines

Clear dosing expectations help patients use budesonide safely and effectively.

Adults with asthma on NHS regimens typically use inhaled budesonide 200–800 µg/day, divided into two doses according to severity and device instructions.

Children start at lower ranges, commonly 100–400 µg/day depending on age and severity, with paediatricians tailoring doses and favouring nebule options where required.

Nebules/respules of 0.25–1 mg per 2 ml remain options for children or severe inpatient management under specialist guidance.

For ileocaecal Crohn’s disease, Entocort 9 mg once daily for up to eight weeks is the usual induction course.

Rectal Budenofalk foam is commonly dosed 2 mg once or twice daily for distal disease for 4–12 weeks.

Adjustment flags: reduce dose in hepatic impairment, start low in older patients and tailor paediatric doses via specialist teams.

Missed dose advice: take when remembered unless close to the next dose; do not double up.

Interactions overview

Patients on multiple medicines often worry about dangerous interactions.

Budesonide has substantial first‑pass hepatic metabolism meaning inhaled forms have low systemic availability at standard doses, but systemic exposure can increase with CYP3A4 inhibitors.

High‑risk interacting drugs include potent CYP3A4 inhibitors such as ketoconazole, itraconazole and certain macrolide antibiotics like clarithromycin, which can raise systemic budesonide levels and increase the risk of systemic corticosteroid adverse effects.

Extra caution is warranted in elderly patients taking multiple medicines.

Herbal CYP inducers such as St John’s wort can reduce budesonide exposure and efficacy, and alcohol may exacerbate corticosteroid‑related harms such as bone loss.

• Avoid concurrent potent CYP3A4 inhibitors where possible or monitor for systemic steroid effects.
• Avoid live vaccines with significant systemic corticosteroid exposure.

Explain the CYP3A4 mechanism briefly to patients: drugs that block liver enzymes can raise steroid levels, so prescribers may change therapy or monitor more closely.

Comparable medicines and prescribing preferences

Clinicians balance efficacy, device and patient preference when choosing between inhaled corticosteroids.

Common alternatives on NHS formularies include fluticasone (Flixotide) and beclometasone (Qvar), with choice influenced by longer action of fluticasone, device preference and local formulary agreements.

For GI disease, budesonide enteric forms are preferred for limited ileocaecal Crohn’s because of local action and reduced systemic effects, while systemic steroids or biologics are options for more extensive or refractory disease.

Frequently asked questions

Patients commonly ask a few key practical questions about budesonide on the NHS.

• Will budesonide make me gain weight? Inhaled budesonide at standard doses has minimal systemic absorption and weight gain is unlikely; systemic steroid forms carry greater risk.
• Can I use my nasal spray and inhaler together? Yes; they act on different sites and can be used together; rinse the mouth after inhaler use to reduce thrush risk.
• Is budesonide safe in pregnancy? Inhaled budesonide is generally preferred when a corticosteroid is needed in pregnancy; discuss with your GP or obstetrician for individual advice.
• What if I miss a dose? Take it when you remember unless it is near the time for your next dose; do not double up.

Guidelines for proper use

Pharmacists are often the most accessible clinical contact for inhaler counselling and adherence support.

Counselling should include device‑specific inhaler technique demonstration and a return demonstration from the patient.

Advise mouth‑rinsing and spitting after inhaled therapy to reduce oral candidiasis and hoarseness risk.

For enteric or systemic regimens, counsel about tapering where indicated, monitoring for adrenal suppression and avoiding potent CYP3A4 inhibitors without specialist advice.

• Provide printed or device‑specific leaflets and document interventions in the NHS record.
• Escalation flow: GP review → Respiratory clinic referral → Hospital admission if acute severe asthma signs appear.

Storage: keep inhalers, nasal sprays and capsules at room temperature (15–30°C) and do not freeze respules/nebules.

Delivery across the United Kingdom